Reduced antibody formation after influenza vaccination in patients with neuromyelitis optica spectrum disorder treated with rituximab
- PMID: 23521577
- DOI: 10.1111/ene.12132
Reduced antibody formation after influenza vaccination in patients with neuromyelitis optica spectrum disorder treated with rituximab
Abstract
Background and purpose: Vaccination against infection becomes important in patients with neuromyelitis optica spectrum disorder (NMOSD) because they are at an increased risk of infection due to long-term immunosuppressive therapy. However, it is unclear whether NMOSD patients under immunosuppression therapy show proper antibody formation after vaccination. Thus the antibody formation after influenza A (H1N1) vaccination in patients with NMOSD receiving rituximab was evaluated.
Methods: The study enrolled 26 patients with NMOSD, nine with multiple sclerosis and eight healthy controls. The enrolled patients had been treated with rituximab (n = 16), mycophenolate mofetil (n = 5), azathioprine (n = 6) and interferon-β (IFN-β) (n = 8). Antibodies against the H1N1 influenza virus were measured in the serum drawn just before (T0) and between 3 and 5 weeks after (T1) vaccination. The immunization states for hepatitis B virus surface antigen, measles and tetanus during the treatment period were also tested.
Results: The rituximab group showed significantly lower geometric mean titer, seroprotection rate and mean fold increase than the azathioprine group, IFN-β group and healthy controls, and a lower seroconversion rate than the IFN-β group. This decrease in vaccination efficacy was also shown in patients receiving mycophenolate mofetil. The immunization state for hepatitis B virus surface antigen, measles and tetanus remained the same during the treatment period with each drug, suggesting that these treatments do not affect previously formed immunity.
Conclusion: This study shows a severely hampered humoral immune response to H1N1 influenza vaccine in patients with NMOSD treated with rituximab, although the vaccination itself is safe in these patients.
© 2013 The Author(s) European Journal of Neurology © 2013 EFNS.
Similar articles
-
The response to vaccination against influenza A(H1N1) 2009, seasonal influenza and Streptococcus pneumoniae in adult outpatients with ongoing treatment for cancer with and without rituximab.Acta Oncol. 2014 Sep;53(9):1212-20. doi: 10.3109/0284186X.2014.914243. Epub 2014 May 28. Acta Oncol. 2014. PMID: 24865118
-
Efficient boosting of the antiviral T cell response in B cell-depleted patients with autoimmune rheumatic diseases following influenza vaccination.Clin Exp Rheumatol. 2013 Sep-Oct;31(5):723-30. Epub 2013 Jun 14. Clin Exp Rheumatol. 2013. PMID: 23806224
-
Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab.Arthritis Rheum. 2010 Jan;62(1):75-81. doi: 10.1002/art.25033. Arthritis Rheum. 2010. PMID: 20039396
-
Monoclonal antibody therapy for neuromyelitis optica spectrum disorder: current and future.Int J Neurosci. 2017 Aug;127(8):735-744. doi: 10.1080/00207454.2016.1242587. Epub 2016 Oct 14. Int J Neurosci. 2017. PMID: 27680606 Review.
-
Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: A systematic review and network meta-analysis.Mult Scler Relat Disord. 2019 Oct;35:246-252. doi: 10.1016/j.msard.2019.08.009. Epub 2019 Aug 9. Mult Scler Relat Disord. 2019. PMID: 31425902 Review.
Cited by
-
Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19.Neurol Neuroimmunol Neuroinflamm. 2021 Jul 14;8(5):e1035. doi: 10.1212/NXI.0000000000001035. Print 2021 Sep. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 34261812 Free PMC article.
-
The Outcome of COVID-19 in Patients with a History of Taking Rituximab: A Narrative Review.Iran J Med Sci. 2021 Nov;46(6):411-419. doi: 10.30476/IJMS.2021.88717.1946. Iran J Med Sci. 2021. PMID: 34840381 Free PMC article. Review.
-
Vaccination of multiple sclerosis patients during the COVID-19 era: Novel insights into vaccine safety and immunogenicity.Mult Scler Relat Disord. 2022 Nov;67:104172. doi: 10.1016/j.msard.2022.104172. Epub 2022 Sep 10. Mult Scler Relat Disord. 2022. PMID: 36116380 Free PMC article. Review.
-
ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs.Mult Scler. 2023 Jul;29(8):904-925. doi: 10.1177/13524585231168043. Epub 2023 Jun 9. Mult Scler. 2023. PMID: 37293841 Free PMC article. Review.
-
Does COVID-19 Vaccination Warrant the Classical Principle "ofelein i mi vlaptin"?Medicina (Kaunas). 2021 Mar 9;57(3):253. doi: 10.3390/medicina57030253. Medicina (Kaunas). 2021. PMID: 33803295 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical